Early data on Hansoh’s HS-20089 were enough to tempt GSK, but Seagen isn't far behind.

Astra manages to avoid the toxicities that scuppered Lilly’s PD-1 x TIM-3 contender, but still needs to dial up sabestomig’s efficacy.

The numerical survival benefit versus Keytruda underperform’s Merck’s phase 3 study, but there’s a possible reason for that.

The latest first-in-human trial entrants include several novel mechanisms, a PSMA radioconjugate and a new pan-KRAS challenger.

Ideaya and GSK join Novartis and Roche in the Werner helicase inhibitor race.

After Exkivity signals another accelerated approval slowdown the Amgen drug tomorrow faces an adcom over its own conditional approval.

And there won’t be a long to wait for the full data, with revelation that Mariposa features among numerous practice-changing late-breakers at ESMO.